» Articles » PMID: 34827174

Cell-Based Neuroprotection of Retinal Ganglion Cells in Animal Models of Optic Neuropathies

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2021 Nov 27
PMID 34827174
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Retinal ganglion cells (RGCs) comprise a heterogenous group of projection neurons that transmit visual information from the retina to the brain. Progressive degeneration of these cells, as it occurs in inflammatory, ischemic, traumatic or glaucomatous optic neuropathies, results in visual deterioration and is among the leading causes of irreversible blindness. Treatment options for these diseases are limited. Neuroprotective approaches aim to slow down and eventually halt the loss of ganglion cells in these disorders. In this review, we have summarized preclinical studies that have evaluated the efficacy of cell-based neuroprotective treatment strategies to rescue retinal ganglion cells from cell death. Intraocular transplantations of diverse genetically nonmodified cell types or cells engineered to overexpress neurotrophic factors have been demonstrated to result in significant attenuation of ganglion cell loss in animal models of different optic neuropathies. Cell-based combinatorial neuroprotective approaches represent a potential strategy to further increase the survival rates of retinal ganglion cells. However, data about the long-term impact of the different cell-based treatment strategies on retinal ganglion cell survival and detailed analyses of potential adverse effects of a sustained intraocular delivery of neurotrophic factors on retina structure and function are limited, making it difficult to assess their therapeutic potential.

Citing Articles

Association Between Glucagon-Like Peptide-1 Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change.

Hallaj S, Halfpenny W, Chuter B, Weinreb R, Baxter S, Cui Q Am J Ophthalmol. 2024; 269:255-265.

PMID: 39237049 PMC: 11634659. DOI: 10.1016/j.ajo.2024.08.030.


Evaluating the impact of mesenchymal stem cell therapy on visual acuity and retinal nerve fiber layer thickness in optic neuropathy patients: a comprehensive systematic review and meta-analysis.

Chaibakhsh S, Azimi F, Shoae-Hassani A, Niknam P, Ghamari A, Dehghan S BMC Ophthalmol. 2024; 24(1):316.

PMID: 39075477 PMC: 11287858. DOI: 10.1186/s12886-024-03588-2.


Analysis of Electric Field Stimulation in Blue Light Stressed 661W Cells.

Bola S, Subramanian P, Calzia D, Dahl A, Panfoli I, Funk R Int J Mol Sci. 2023; 24(4).

PMID: 36834840 PMC: 9965974. DOI: 10.3390/ijms24043433.

References
1.
Williams P, Morgan J, Votruba M . Mouse models of dominant optic atrophy: what do they tell us about the pathophysiology of visual loss?. Vision Res. 2010; 51(2):229-34. DOI: 10.1016/j.visres.2010.08.031. View

2.
Dreixler J, Poston J, Balyasnikova I, Shaikh A, Tupper K, Conway S . Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats. Invest Ophthalmol Vis Sci. 2014; 55(6):3785-96. PMC: 4062399. DOI: 10.1167/iovs.13-11683. View

3.
Hellstrom M, Pollett M, Harvey A . Post-injury delivery of rAAV2-CNTF combined with short-term pharmacotherapy is neuroprotective and promotes extensive axonal regeneration after optic nerve trauma. J Neurotrauma. 2011; 28(12):2475-83. DOI: 10.1089/neu.2011.1928. View

4.
Zhang Q, Lai D . Application of human amniotic epithelial cells in regenerative medicine: a systematic review. Stem Cell Res Ther. 2020; 11(1):439. PMC: 7559178. DOI: 10.1186/s13287-020-01951-w. View

5.
Koeberle P, Bahr M . The upregulation of GLAST-1 is an indirect antiapoptotic mechanism of GDNF and neurturin in the adult CNS. Cell Death Differ. 2007; 15(3):471-83. DOI: 10.1038/sj.cdd.4402281. View